Cantor Fitzgerald reiterated their neutral rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $165.00 price target on the biopharmaceutical company’s stock. Several other equities analysts have also recently weighed in on ALNY. Needham & Company LLC reiterated a buy […]
International Biotechnology Trust (LON:IBT) Share Price Passes Above Two Hundred Day Moving Average of $621 02 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.